Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
RESEARCH TOOLSreports
Holding DAWN?
Track your performance easily
DAWN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.94 - $18.07
Previous Close$12.79
Volume2.28M
Average Volume (3M)1.11M
Market Cap
$1.26B
Enterprise Value$700.78M
Total Cash (Recent Filing)$558.38M
Total Debt (Recent Filing)$2.62M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Mar 10, 2025EPS Estimate
-$0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding100,846,294
10 Day Avg. Volume965,699
30 Day Avg. Volume1,107,819
Standard Deviation0.32
R-Squared0.05
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)2.32
Price to Sales (P/S)12.32
Price to Cash Flow (P/CF)6.20
P/FCF Ratio6.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.87
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-7.76
Forecast
1Y Price Target
$35.57Price Target Upside178.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Day One Biopharmaceuticals News
PremiumCompany Announcements
Day One Biopharmaceuticals Announces Leadership Transition
PremiumCompany Announcements
Day One Biopharmaceuticals Reports Strong Q3 Growth
PremiumCompany Announcements
Day One Biopharmaceuticals Reports Strong Q3 with OJEMDABulls Say, Bears Say
Bulls Say
Growth PotentialThe company has only penetrated a fraction of the total potential prescriber base for Ojemda, indicating room for growth.
Market AcceptanceOjemda sales significantly exceeded expectations, suggesting strong market acceptance.
Revenue PerformanceDay One reported strong Q3 Ojemda revenue of $20.1MM, which was ahead of consensus by 33%.
Bears Say
Clinical DevelopmentClinical assets may fail to demonstrate adequate safety and/or efficacy in the clinic.
Market IndicatorsMany investors are focused on new patient adds as a better leading indicator of continued scripts growth, indicating some concerns in this area.
Product SafetyPfizer and AbbVie discontinued development of a similar anti-PTK7 ADC due to toxicity issues, which may be a concern for DAY301.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
DAWN FAQ
What was Day One Biopharmaceuticals’s price range in the past 12 months?
Day One Biopharmaceuticals lowest stock price was $11.94 and its highest was $18.07 in the past 12 months.
What is Day One Biopharmaceuticals’s market cap?
Currently, no data Available
When is Day One Biopharmaceuticals’s upcoming earnings report date?
Day One Biopharmaceuticals’s upcoming earnings report date is Mar 10, 2025 which is in 78 days.
How were Day One Biopharmaceuticals’s earnings last quarter?
Day One Biopharmaceuticals released its earnings results on Oct 30, 2024. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of -$0.316 by $0.696.
Is Day One Biopharmaceuticals overvalued?
According to Wall Street analysts Day One Biopharmaceuticals’s price is currently Undervalued.
Does Day One Biopharmaceuticals pay dividends?
Day One Biopharmaceuticals does not currently pay dividends.
What is Day One Biopharmaceuticals’s EPS estimate?
Day One Biopharmaceuticals’s EPS estimate is -$0.46.
How many shares outstanding does Day One Biopharmaceuticals have?
Day One Biopharmaceuticals has 100,846,290 shares outstanding.
What happened to Day One Biopharmaceuticals’s price movement after its last earnings report?
Day One Biopharmaceuticals reported an EPS of $0.38 in its last earnings report, beating expectations of -$0.316. Following the earnings report the stock price went up 1.728%.
Which hedge fund is a major shareholder of Day One Biopharmaceuticals?
Among the largest hedge funds holding Day One Biopharmaceuticals’s share is RA Capital Management. It holds Day One Biopharmaceuticals’s shares valued at 110M.
---
Day One Biopharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.57 (178.11% Upside)
$35.57 (178.11% Upside)
Blogger Sentiment
Bullish
DAWN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 3.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.65%
12-Months-Change
Fundamentals
Return on Equity
-17.84%
Trailing 12-Months
Asset Growth
45.06%
Trailing 12-Months
Company Description
Day One Biopharmaceuticals
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
---
DAWN Company Deck
---
DAWN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong positive tone with significant revenue growth from the successful launch of OJEMDA, substantial financial strength, and progress in pipeline expansion. However, increased operating expenses and expected challenges in market penetration were noted.Read More>---
DAWN Stock 12 Month Forecast
Average Price Target
$35.57
▲(178.11% Upside)
Technical Analysis
Fulcrum Therapeutics
―
Syros Pharmaceuticals
―
Karyopharm Therapeutics
―
Blueprint Medicines
―
Best Analysts Covering DAWN
1 Year
1 Year Success Rate
5/12 ratings generated profit
1 Year Average Return
+4.12%
reiterated a buy rating 5 months ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of +4.12% per trade.
---